Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Pioglitazone: effect on CYP3A4 activity.

Sandra N Nowak1, David J Edwards, Anthony Clarke

  • 1Wayne State University, Department of Pharmacy Practice, Detroit, Michigan, USA.

Journal of Clinical Pharmacology
|December 5, 2002
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Regional Nasal Drug Deposition in Pediatric vs. Adult Models: In vitro Insights into User Technique and Breathing Patterns Sensitivity.

Pharmaceutical research·2026
Same author

Large row-constrained supersaturated designs for high-throughput screening.

Biometrics·2025
Same author

Cytisinicline for Smoking Cessation: The ORCA Phase 3 Replication Randomized Clinical Trial.

JAMA internal medicine·2025
Same author

Uncovering the genome of leading indicators from lagging indicators and normative documents: A proof-of-concept study.

Journal of safety research·2025
Same author

Development of a predictive model for pediatric intranasal drug delivery with nasal sprays: Leveraging intersubject variability in anatomical dimensions, administration-related parameters, and airway patency.

Computers in biology and medicine·2025
Same author

COVID-19 outbreaks in nursing homes in Los Angeles County, March 2020-April 2022.

Infection control and hospital epidemiology·2025
Same journal

How to Replace the TQT Study-The Use of Concentration-QTc Modeling to Exclude a Small Effect of a Novel Drug on QT Interval: Historical Perspective and Implementation.

Journal of clinical pharmacology·2026
Same journal

Genome Sequencing Enhances Precision and Clinical Utility of Pharmacogenetic Data Compared to Arrays.

Journal of clinical pharmacology·2026
Same journal

FDA Gene Therapy Approvals (1998-2025): Current Status, Regulatory Evolution, and Future Directions.

Journal of clinical pharmacology·2026
Same journal

Human Disposition, Metabolism, and Excretion of Sevasemten (EDG-5506), a Selective Modulator of Fast Myosin in Healthy Volunteers.

Journal of clinical pharmacology·2026
Same journal

New Insights into Genetic Polymorphisms Influencing the Therapeutic Efficacy and Toxicity of Rivaroxaban.

Journal of clinical pharmacology·2026
Same journal

Physiologically Based Pharmacokinetic Modeling to Predict the Pharmacokinetics of Sacubitril/Valsartan in the Elderly with Renal or Hepatic Impairment Population.

Journal of clinical pharmacology·2026
See all related articles

Pioglitazone therapy did not significantly affect CYP3A4 enzyme activity in healthy volunteers. This suggests pioglitazone does not alter the pharmacokinetics of other drugs metabolized by this enzyme.

Area of Science:

  • Pharmacology
  • Drug Metabolism
  • Clinical Pharmacology

Background:

  • Troglitazone, a related thiazolidinedione, is known to induce CYP3A4 enzyme activity.
  • Pioglitazone is a widely used medication for type 2 diabetes mellitus.

Purpose of the Study:

  • To investigate the effect of multiple-dose pioglitazone therapy on CYP3A4 enzyme activity.
  • To assess CYP3A4 activity using the urinary 6-beta-hydroxycortisol to cortisol ratio.

Main Methods:

  • Prospective, open-label study in 12 healthy volunteers.
  • Pioglitazone hydrochloride (45 mg daily) administered for 14 days.
  • Urinary 6-beta-hydroxycortisol/cortisol ratio measured before and after treatment.

Main Results:

Related Experiment Videos

  • The mean urinary 6-beta-hydroxycortisol/cortisol ratio showed a non-significant increase of 20.2% (p=0.29).
  • Nine subjects experienced a slight increase, while three showed a decrease in the ratio.
  • No statistically significant change in CYP3A4 activity was observed.

Conclusions:

  • Multiple-dose pioglitazone therapy does not appear to induce CYP3A4 enzyme activity.
  • Pioglitazone is unlikely to cause clinically significant pharmacokinetic interactions with other CYP3A4 substrates.